Here, the authors leveraged genetic and proteomic information from the UK Biobank and two randomized controlled trials to characterize how polygenic disease risk for T2D and related comorbidities perturbs the plasma proteome and glean therapeutic insights.
- Douglas P. Loesch
- Manik Garg
- Michael Inouye